Rubin Lubomirov

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Topics

Squamous Cell Carcinoma

Top Venues

Cancer chemotherapy and pharmacology

Clinical pharmacokinetics

This page only lists publications with an associated author ORCID identifier.

Publications

Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Sara Martínez, Jorge Luis Iglesias, Román Octavio Calafati, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study. Marine drugs 22 (4) (2024)
Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Sara Martínez, Jorge Luis Iglesias, Román Octavio Calafati, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study. Marine drugs 22 (4) (2024)
Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Sara Martínez, Jorge Luis Iglesias, Román Octavio Calafati, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study. Marine drugs 22 (4) (2024)
Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Sara Martínez, Jorge Luis Iglesias, Román Octavio Calafati, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study. Marine drugs 22 (4) (2024)
Nicholas King, Soledad Garcia-Martinez, Eider Alcaraz, Alba Grisalena, Rubin Lubomirov, Raquel Altares, Carlos Fernandez-Teruel, Andrés M Francesch, Pablo M Avilés, Salvador Fudio
Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC-MS/MS. PloS one 18 (3) (2023)
Nicholas King, Soledad Garcia-Martinez, Eider Alcaraz, Alba Grisalena, Rubin Lubomirov, Raquel Altares, Carlos Fernandez-Teruel, Andrés M Francesch, Pablo M Avilés, Salvador Fudio
Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC-MS/MS. PloS one 18 (3) (2023)
Nicholas King, Soledad Garcia-Martinez, Eider Alcaraz, Alba Grisalena, Rubin Lubomirov, Raquel Altares, Carlos Fernandez-Teruel, Andrés M Francesch, Pablo M Avilés, Salvador Fudio
Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC-MS/MS. PloS one 18 (3) (2023)
Nicholas King, Soledad Garcia-Martinez, Eider Alcaraz, Alba Grisalena, Rubin Lubomirov, Raquel Altares, Carlos Fernandez-Teruel, Andrés M Francesch, Pablo M Avilés, Salvador Fudio
Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC-MS/MS. PloS one 18 (3) (2023)
Salvador Fudio, Alvaro Sellers, Laura Pérez Ramos, Beatriz Gil-Alberdi, Ali Zeaiter, Mikel Urroz, Antonio Carcas, Rubin Lubomirov
Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics. Cancer chemotherapy and pharmacology 90 (4) (2022)
Carlos Fernández-Teruel, Salvador Fudio, Rubin Lubomirov
Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer. Cancer chemotherapy and pharmacology (2021)
Salvador Fudio, Josep Tabernero, Vivek Subbiah, Sant P Chawla, Victor Moreno, Federico Longo, Rafael Lopez, Antonio Anton, Jose Manuel Trigo, Geoffrey Shapiro, Woondong Jeong, Victor Manuel Villalobos, Rubin Lubomirov, Carlos Fernández-Teruel, Vicente Alfaro, Valentina Boni
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis. Cancer chemotherapy and pharmacology 87 (1) (2020)
Carlos Fernández-Teruel, Ignacio González-García, Iñaki F Trocóniz, Rubin Lubomirov, Arturo Soto, Salvador Fudio
Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer. Clinical pharmacokinetics 58 (3) (2020)